BPC-157: A Research Overview of the Pentadecapeptide

BPC-157 is a synthetic pentadecapeptide — a chain of 15 amino acids — with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is registered under CAS number 137525-51-0 and appears in the literature under several aliases, most commonly PL 14736 and “Body Protection Compound 157.” The name reflects its reported derivation: it corresponds to a partial sequence within a protein identified in gastric juice, and early Croatian work (the Pliva/Sikiric group) characterized it as a “stable gastric pentadecapeptide” because, unlike many native peptides, it remained intact in human gastric juice for extended periods in their assays.

Structurally the molecule is compact and unusual. Three consecutive proline residues at positions 3–5 impose rigid backbone geometry, the glutamate and aspartate residues give it a slightly acidic isoelectric point (around pH 4.5), and there are no disulfide bridges or internal cyclization. Its molecular formula is C62H98N16O22 with an average molecular weight of roughly 1419.55 g/mol. These properties matter for experimental design: solubility, charge, and the absence of cysteines all bear on reconstitution, buffer selection, and analytical confirmation. The full analytical profile — formula, mass, purity specification, and certificate-of-analysis methodology — is documented separately on the BPC-157 chemistry data sheet.

The published record on BPC-157 is dominated by preclinical work. The earliest and most extensive body of studies originates from a single research program led by Predrag Sikiric and colleagues in Zagreb, which over roughly 30 years generated reports across gastrointestinal, musculoskeletal, vascular, and neural injury models in rats and mice. Independent groups — notably in Taiwan (Hsieh and colleagues) and China (Huang, Xue and others) — later contributed mechanistic and wound-healing studies, broadening the literature beyond its original source.

It is important to characterize this evidence base accurately. The overwhelming majority of BPC-157 publications are rodent in-vivo studies or in-vitro cell experiments. Controlled human clinical trial data are extremely limited; the compound's history includes early-phase clinical evaluation under the PL 14736 designation for inflammatory bowel disease, but there is no large, replicated clinical evidence base of the kind that supports approved drugs. Researchers summarizing the field should therefore weight preclinical breadth against clinical scarcity. A structured, citation-level treatment of the literature — including study counts, model types, and evidence quality — is maintained on the BPC-157 studies library, while a thematic summary organized by research domain is maintained on the BPC-157 research findings page.

No single mechanism fully accounts for the range of effects reported in BPC-157 animal studies, and the proposed mechanisms below are drawn from preclinical work — predominantly rat models and cultured cells. They describe hypotheses and observations in those systems, not established pharmacology in humans.

The most frequently invoked mechanism is modulation of angiogenesis. In rat models of crushed and transected muscle and tendon, the angiogenic effect attributed to BPC-157 was correlated with up-regulation of vascular endothelial growth factor (VEGF) expression in healing tissue (Brcic et al., 2009; PMID 20388964). In endothelial cell and rat-based experiments, BPC-157 was associated with increased expression and internalization of the VEGFR2 receptor and with activation of the downstream VEGFR2–Akt–eNOS signaling axis, which those authors linked to pro-angiogenic activity (Hsieh et al., 2017; PMID 27847966).

A closely related theme is interaction with the nitric oxide (NO) system. In isolated rat aorta and endothelial preparations, BPC-157 was reported to induce NO generation associated with the Src–Caveolin-1–eNOS pathway, with the vasodilatory effect abolished by the NOS inhibitor L-NAME and by hemoglobin (Hsieh et al., 2020; PMID 33051481). A review of rodent studies further describes the peptide as competing with both L-arginine and L-arginine analogues in their effects on the NO pathway across various injury models (Sikiric et al., 2014; PMID 23755725).

At the tissue-repair level, additional candidate mechanisms have been reported: enhanced granulation and collagen organization with stimulation of the early growth response gene egr-1 and its co-repressor NAB2 in rat wound models and cultured cells (Tkalcevic et al., 2007; PMID 17628536), and increased growth hormone receptor expression in cultured tendon fibroblasts at both mRNA and protein levels (Chang et al., 2014; PMID 25415472). A review comparing BPC-157 with standard angiogenic growth factors such as VEGF, EGF, and FGF situates these effects within the broader growth-factor signaling landscape across gastrointestinal, tendon, ligament, muscle, and bone models (Seiwerth et al., 2018; PMID 29998800).

The preclinical literature clusters into a few recurring injury-model domains. The summaries below report what specific studies observed in their experimental systems; they are not claims about human outcomes.

Musculoskeletal models account for much of the record. In a rat surgically transected medial collateral ligament model, BPC-157 (given intraperitoneally, orally, or topically) was associated with consistent functional, biomechanical, macroscopic, and histological improvement in ligament healing relative to controls across a 90-day window (Cerovecki et al., 2010; PMID 20225319). In a rat Achilles tendon-to-bone detachment model, administration was associated with improved functional recovery and appeared to counteract impairment of healing produced by concurrent corticosteroid administration (Krivic et al., 2006; PMID 16583442). In rats with a transected Achilles tendon, treatment was reported to improve biomechanical, functional, and histological parameters, and in vitro it was associated with increased outgrowth of cultured tendon fibroblasts (Staresinic et al., 2003; PMID 14554208). In a model of quadriceps tendon detachment from muscle — a disabled myotendinous junction — administration was associated with reduced progressive muscle atrophy (Japjec et al., 2021; PMID 34829776).

Gastrointestinal models reflect the compound's origins. In rat models of induced gastric ulceration, BPC-157 was associated with dose-dependent reductions in ulcer formation, with reported inhibition ratios of roughly 45.7% to 65.6% relative to controls (Xue et al., 2004; PMID 15052688). In a rat reflux oesophagitis model, treated groups showed fewer inflammatory cells across assessed time points (Sikiric et al., 1999; PMID 10672991), and in distended-stomach experiments discussed in the context of inflammatory bowel disease evaluation, intragastric administration was associated with a relatively constant gastric vascular presentation versus controls (Sikiric et al., 2006; PMID 17186181).

Wound and neural models round out the picture. In a rodent alkali-burn model, treatment was associated with accelerated wound closure, increased granulation and collagen deposition, with in-vitro promotion of proliferation, migration, and tube-formation activity (Huang et al., 2015; PMID 25995620). In a rat spinal cord injury model, treated animals were reported to show progressively better tail motor function and reduced microscopic injury features by around day 15 (Perovic et al., 2019; PMID 31266512). For a fuller, domain-organized treatment of these outcomes, see the BPC-157 research findings page; for the underlying study-by-study citations and evidence grading, see the BPC-157 studies library.

The questions below recur most often when investigators evaluate BPC-157 for laboratory work. They are answered in a research-context, regulatory, and handling frame — not as guidance for human use.